BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30803844)

  • 1. Formulation of aluminum hydroxide adjuvant with TLR agonists poly(I:C) and CpG enhances the magnitude and avidity of the humoral immune response.
    Lu F; Mosley YC; Carmichael B; Brown DD; HogenEsch H
    Vaccine; 2019 Mar; 37(14):1945-1953. PubMed ID: 30803844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
    Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
    Inglefield J; Catania J; Harris A; Hickey T; Ma Z; Minang J; Baranji K; Spangler T; Look J; Ruiz C; Lu H; Alleva D; Reece JJ; Lacy MJ
    Vaccine; 2022 Sep; 40(38):5544-5555. PubMed ID: 35773119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro.
    Morefield GL; Sokolovska A; Jiang D; HogenEsch H; Robinson JP; Hem SL
    Vaccine; 2005 Feb; 23(13):1588-95. PubMed ID: 15694511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
    Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
    Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
    Tada H; Aiba S; Shibata K; Ohteki T; Takada H
    Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity.
    Lisk C; Yuen R; Kuniholm J; Antos D; Reiser ML; Wetzler LM
    Front Immunol; 2021; 12():624197. PubMed ID: 33815376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.
    Beck Z; Torres OB; Matyas GR; Lanar DE; Alving CR
    J Control Release; 2018 Apr; 275():12-19. PubMed ID: 29432824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
    Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
    Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic background influences the cellular and humoral immune responses to vaccines.
    Zeng M; Nourishirazi E; Guinet E; Nouri-Shirazi M
    Clin Exp Immunol; 2016 Nov; 186(2):190-204. PubMed ID: 27393001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
    Jin JW; Tang SQ; Rong MZ; Zhang MQ
    Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resiquimod (R848) has more stronger immune adjuvantivity than other tested TLR agonists].
    Shen Y; Zeng M; Qiu F; Tang H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):591-596. PubMed ID: 28502294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model.
    Ma Y; Poisson L; Sanchez-Schmitz G; Pawar S; Qu C; Randolph GJ; Warren WL; Mishkin EM; Higbee RG
    Immunology; 2010 Jul; 130(3):374-87. PubMed ID: 20331478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
    Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
    J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine.
    Vreman S; McCaffrey J; Popma-de Graaf DJ; Nauwynck H; Savelkoul HFJ; Moore A; Rebel JMJ; Stockhofe-Zurwieden N
    Vet Immunol Immunopathol; 2019 Jun; 212():27-37. PubMed ID: 31213249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.
    Julier Z; de Titta A; Grimm AJ; Simeoni E; Swartz MA; Hubbell JA
    Vaccine; 2016 May; 34(21):2453-2459. PubMed ID: 27016652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
    Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
    Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The orientation of CpG conjugation on aluminum oxyhydroxide nanoparticles determines the immunostimulatory effects of combination adjuvants.
    Liang Z; Bao H; Yao Z; Li M; Chen C; Zhang L; Wang H; Guo Y; Ma Y; Yang X; Yu G; Zhang J; Xue C; Sun B; Mao C
    Biomaterials; 2024 Jul; 308():122569. PubMed ID: 38626556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.